AGEN Stock Overview
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.14|
|52 Week High||US$6.79|
|52 Week Low||US$1.25|
|1 Month Change||9.03%|
|3 Month Change||90.30%|
|1 Year Change||-46.87%|
|3 Year Change||10.56%|
|5 Year Change||-13.02%|
|Change since IPO||-99.15%|
Recent News & Updates
Agenus GAAP EPS of -$0.17, revenue of $20.93M
Agenus press release (NASDAQ:AGEN): Q2 GAAP EPS of -$0.17. Revenue of $20.93M (+95.1% Y/Y). The company ended second quarter 2022 with a cash and short-term investment balance of $238 million as compared to $263 million and $307 million on March 31, 2022, and December 31, 2021, respectively. Shares +2% PM.
Agenus: Successfully Pulled Itself Away From Disaster
Agenus was looking at a disaster last year after it pulled its BLA. However, after reporting strong early data from 1181, it looks to be on a much more solid footing. Current lows and cash balance make it very interesting. Agenus (AGEN) had a disruptive 2021, when its accelerated approval BLA for balstilimab in 2nd line cervical cancer had to be withdrawn under unhappy circumstances, and its self-declared key asset, next-generation CTLA-4 agent, AGEN1181 (botensilimab), produced some promising early data in a group of solid tumors. However, the BLA withdrawal determined the stock's price action - the company was cut to nearly half in size in terms of market valuation. Botensilimab scored another win just last week when on June 29, the company announced positive early-stage data for botensilimab and balstilimab combination in patients with microsatellite stable or MSS colorectal cancer. MSS CRC is a very difficult to treat form of CRC. MSS occurs in up to 85% of all CRC patients. A microsatellite is a chain of DNA repeats. When these microsatellites occur in the same number throughout the body, it is considered stable; otherwise, it is microsatellite instability or MSI. This is classified as MSI-HIGH, MSI-LOW and MSS. Research has shown that MSI-HIGH CRC patients have a much better prognosis than MSI-LOW or MSS patients. However, many drugs, for example Keytruda, are only approved for MSI-HIGH CRC patients; the more difficult to treat MSI-L/MSS CRC patients have fewer options. Tumors with the MSS phenotype "often exhibit a lower tumor mutation burden and fewer tumor-infiltrating lymphocytes than dMMR/MSI-H, leading to immune tolerance and evasion in the tumor microenvironment." Thus, currently approved or pipeline immunotherapies often have very low ORR or disease control rates in the CRC population: Peer trial data (Research report) With that background in mind, it is interesting to see that Agenus' combo therapy worked very well in the MSS population. This phase 1b study evaluated 1 or 2 mg/kg of the anti-CTLA-4 compound, botensilimab, and 3 mg/kg of anti-PD-1 molecule balstilimab in patients with microsatellite stable colorectal cancer (MSS CRC). Patients were heavily pretreated, with a median of 4 prior lines of therapy, including about a third of the patients having previously received immunotherapy. 41 patients were evaluable at data cutoff, and these demonstrated a 24% overall response rate. This is interesting because a major trial of Keytruda showed a 0% response rate in an MSS CRC patient population (n=18), and many other immunotherapies, as we saw in the table above, saw very poor ORR. Other elements of the data were: The disease control rate, a measure combining partial response and stable disease, stood at 73%, while 50% of objective responses were found to have more than 50% tumor reduction. In terms of durability, 80% of objective responses were ongoing as of the data cutoff, with 30% of objective responses exceeding one year. Botensilimab was well tolerated during the study, the company said, noting that there were no grade 4/5 treatment-related adverse events. The discussion above shows Botensilimab's potential. Agenus had a lot of bad luck with balstilimab, but as I discussed before, balstilimab monotherapy was something of a non-starter to begin with, and the BRAVA trial was going to cost them probably more than they could make from balstilimab monotherapy. Now they have a drug with better potential, they are planning to run a series of phase 2 trials investigating botensilimab as monotherapy and in combination with balstilimab in MSS-CRC and gynecological cancers (ovarian and MSS-endometrial cancer), and it appears from early indications that they may do very well in the trial.
|AGEN||US Biotechs||US Market|
Return vs Industry: AGEN underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: AGEN underperformed the US Market which returned -10.2% over the past year.
|AGEN Average Weekly Movement||13.4%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Fundamentals Summary
|AGEN fundamental statistics|
Is AGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGEN income statement (TTM)|
|Cost of Revenue||US$188.09m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.064|
|Net Profit Margin||5.65%|
How did AGEN perform over the long term?See historical performance and comparison
Is AGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AGEN?
Other financial metrics that can be useful for relative valuation.
|What is AGEN's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does AGEN's PE Ratio compare to its peers?
|AGEN PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ORGO Organogenesis Holdings
CDMO Avid Bioservices
CPRX Catalyst Pharmaceuticals
Price-To-Earnings vs Peers: AGEN is expensive based on its Price-To-Earnings Ratio (49.2x) compared to the peer average (31.9x).
Price to Earnings Ratio vs Industry
How does AGEN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: AGEN is expensive based on its Price-To-Earnings Ratio (49.2x) compared to the US Biotechs industry average (15.9x)
Price to Earnings Ratio vs Fair Ratio
What is AGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||49.2x|
|Fair PE Ratio||24.8x|
Price-To-Earnings vs Fair Ratio: AGEN is expensive based on its Price-To-Earnings Ratio (49.2x) compared to the estimated Fair Price-To-Earnings Ratio (24.8x).
Share Price vs Fair Value
What is the Fair Price of AGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AGEN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Agenus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGEN's forecast earnings growth (12.9% per year) is above the savings rate (1.9%).
Earnings vs Market: AGEN's earnings (12.9% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: AGEN's earnings are forecast to grow, but not significantly.
Revenue vs Market: AGEN's revenue (20.1% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: AGEN's revenue (20.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGEN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Agenus performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGEN has a large one-off gain of $18.3M impacting its June 30 2022 financial results.
Growing Profit Margin: AGEN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AGEN has become profitable over the past 5 years, growing earnings by 12.4% per year.
Accelerating Growth: AGEN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AGEN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: Whilst AGEN's Return on Equity (72.09%) is outstanding, this metric is skewed due to their high level of debt.
Discover strong past performing companies
How is Agenus's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AGEN's short term assets ($288.9M) exceed its short term liabilities ($159.7M).
Long Term Liabilities: AGEN's short term assets ($288.9M) exceed its long term liabilities ($282.8M).
Debt to Equity History and Analysis
Debt Level: AGEN has more cash than its total debt.
Reducing Debt: AGEN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: AGEN's debt is well covered by operating cash flow (92%).
Interest Coverage: AGEN's interest payments on its debt are not well covered by EBIT (0.8x coverage).
Discover healthy companies
What is Agenus's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AGEN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Garo Armen (69 yo)
Dr. Garo H. Armen, Ph D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. He serves as Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairm...
CEO Compensation Analysis
Compensation vs Market: Garo's total compensation ($USD9.76M) is above average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Garo's compensation has been consistent with company performance over the past year.
Experienced Management: AGEN's management team is considered experienced (3.4 years average tenure).
Experienced Board: AGEN's board of directors are seasoned and experienced ( 15.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.5%.
Agenus Inc.'s employee growth, exchange listings and data sources
- Name: Agenus Inc.
- Ticker: AGEN
- Exchange: NasdaqCM
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$840.994m
- Shares outstanding: 283.16m
- Website: https://www.agenusbio.com
Number of Employees
- Agenus Inc.
- 3 Forbes Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.